Preparation, Optimization, and Characterization of Topotecan Loaded PEGylated Liposomes Using Factorial Design

REFERENCES

• Biloti D. N., Santana M. H., Pessine F. B. Lipid membrane with low proton permeability. Biochim. Biophys Acta. 2003; 1611: 1–4
   PubMed Web of Science ®Google Scholar
• Broom C. Clinical studies of topotecan. Ann. N. Y. Acad. Sci. 1996; 803: 264–271
   PubMed Web of Science ®Google Scholar
• Burke T. G., Mishra A. K., Wani M. C., Wall M. E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 1993; 32: 5352–5364
   PubMed Web of Science ®Google Scholar
• Chang C. W., Barber L., Ouyang C., Masin D., Bally M. B., Madden T. D. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br. J. Cancer 1997; 75: 169–177
   PubMed Web of Science ®Google Scholar
• Cullis P. R., Bally M. B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49: 5922–5930
   PubMed Web of Science ®Google Scholar
• Cullis P. R., Hope M. J., Bally M. B., Madden T. D., Mayer L. D. Liposomes as pharmaceuticals. Liposomes: Rational design., M. J. Ostro. Marcel Dekkar, New York 1987; 39–72
   Google Scholar
• Daemen T., Regts J., Meesters M., Ten Kate M. T., Bakker-Woudenberg I. A. J. M., Scherphof G. L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release 1997; 44: 1–9
   Web of Science ®Google Scholar
• Dunton C. J. New options for the treatment of advanced ovarian cancer. Semin. Oncol. 1997; 24: S5-2–S5-11
   Google Scholar
• El-Gibaly I., Abdel-Ghaffar S. K. Effect of hexacosanol on the characteristics of novel sustained-release allopurinol solid lipospheres (SLS): Factorial design application and product evaluation. Int. J. Pharm. 2005; 294: 33–51
   PubMed Web of Science ®Google Scholar
• Emerson D.L. Liposomal delivery of camptothecins. PSTT 2000; 3: 205–209
   PubMedGoogle Scholar
• Fassberg J., Stella V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992; 81: 676–684
   PubMed Web of Science ®Google Scholar
• Franz T. J. On the diffusion of tritiated water through skin. J. Invest. Dermatol. 1968; 50: 260
   PubMed Web of Science ®Google Scholar
• Gabizon A., Goren D., Cohen R., Barenholz Y. Development of liposomal anthracyclines: From basics to clinical applications. J. Control Release 1998; 53: 275–279
   PubMed Web of Science ®Google Scholar
• Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C. G., Rabello E., Cass Y., Peretz T., Sulkes A., Chisin R., Berenholz Y. Clinical studies of liposome encapsulated doxorubicin. Acta Oncol. 1994; 33: 779–786
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes as drug carriers: Recent trends and progress. John Wiley and Sons, New York 1988
   Google Scholar
• Hertzberg R. P., Caranfa M. J., Holden H. G. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715–720
   PubMed Web of Science ®Google Scholar
• Herzog T. J. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 2002; 7(Suppl. 5)3–10
   PubMedGoogle Scholar
• Hochster H., Liebes L., Speyer J. Phase I trial of low-dose continuous TPT infusion in patients with cancer: An active and well-tolerated regimen. J. Clin. Oncology 1994; 12: 553–559
   PubMed Web of Science ®Google Scholar
• Hope M. J., Bally M. B., Webb G., Cullis P. R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 1985; 812: 55–65
   PubMed Web of Science ®Google Scholar
• Kingsbury W. D., Boehm J. C., Jakas D. R. Synthesis of water-soluble (aminoalkyl)-camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 1991; 34: 98–107
   PubMed Web of Science ®Google Scholar
• Liebmann J., Cook J. A., Lipschultz C., Teague D., Fischer J., Mitchell J. B. The influence of cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human cell lines. Cancer Chemother. Pharmacol. 1994; 33: 331–339
   PubMed Web of Science ®Google Scholar
• Lim H., Masin D., Madden T. D., Bally M. B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther. 1997; 281: 566–573
   PubMed Web of Science ®Google Scholar
• Maruyama K., Okuizumi S., Ishida O., Yamauchi H., Kikuchi H., Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 1994; 111: 103–107
   Web of Science ®Google Scholar
• Mayer L. D., Nayar R., Thies R. L., Boman N. L., Cullis P. R., Bally M. B. Identification of vesicle properties that enhance the anti-tumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother. Pharmacol. 1993; 33: 17–24
   PubMed Web of Science ®Google Scholar
• Nygren P., Csoka K., Jonsson B., Fridborg H., Bergh J., Hagberg H., Glimelius B., Brodin O., Tholander B., Kreuger A., Lönnerholm G., Jakobsson A., Olsen L., Kristensen J., Larsson R. The cytotoxic activity of taxol in primary cultures of tumor cells from patients is partly mediated by cremophor EL. Br. J. Cancer 1995; 71: 478–481
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D. Steric stabilization an overview. Liposomes rational design, A. S. Janoff. Marcel Dekker, New York 1999; 1–12
   Google Scholar
• Pizzolato J. F., Saltz L. B. The camptothecins. Lancet 2003; 361: 2235–2242
   PubMed Web of Science ®Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. I. Fickian and non-Fickian release from nonswellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Rel. 1987; 5: 23–36
   Google Scholar
• Rowinsky E. K., Donehower R. C. Paclitaxel (Taxol). N. Engl. J. Med. 1995; 332: 1004–1014
   PubMed Web of Science ®Google Scholar
• Santana V. M., Zamboni W. C., Kirstein M. N., Tan M., Liu T., Gajjar A., Houghton P. J., Stewart C. F. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res. 2003; 9: 633–640
   PubMed Web of Science ®Google Scholar
• Santos N. D., Waterhouse D., Masin D., Tardi P. G., Karlsson G., Edwards K., Bally M. B. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J. Control. Release 2005; 105: 89–105
   PubMed Web of Science ®Google Scholar
• Sharma A., Straubinger R. M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 1994; 11: 889–896
   PubMed Web of Science ®Google Scholar
• Sharma U. S., Balasubramanian S. V., Straubinger R. M. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 1995; 84: 1223–1230
   PubMed Web of Science ®Google Scholar
• Siepmann J., Peppas N. A. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Del Rev 2003; 48: 139–157
   Web of Science ®Google Scholar
• Sykes E., Woodburn K., Decker D., Kessel D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer 1994; 70: 401–404
   PubMed Web of Science ®Google Scholar
• Unezaki S., Maruyama K., Ishida O., Suginaka A., Hosoda J., Iwatsuru M. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipatic poly(ethylene glycol). Int. J. Pharm. 1995; 126: 41–48
   Web of Science ®Google Scholar
• Vali A. M., Shafaghi B., Dadashzadeh S. Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 818: 205–212
   PubMed Web of Science ®Google Scholar
• Webb M. S., Harasym T. O., Masin D., Bally M. B., Mayer L. D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetics and therapeutic properties of vincristine in murine and human tumor models. Br. J. Cancer 1995; 72: 896–904
   PubMed Web of Science ®Google Scholar
• Weiss R. B., Donehower R. C., Wiernik P. H., Ohnuma T., Gralla R. L., Trump D., Baker J. R., VanEcho D. A., VonHoff D. D., Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990; 8: 1263–1268
   PubMed Web of Science ®Google Scholar
• Zhang J. Q., Zhang Z. R., Yang H., Tan Q. Y., Qin S. R., Qiu X. L. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res. 2005; 22: 573–583
   PubMed Web of Science ®Google Scholar